Antitumor Antibiotics

1. Front Matter

   Pages I-IX

   PDF

2. Summary of Clinical Data on Antitumor Antibiotics in Japan

   • Y. Koyama

   Pages 1-19

3. Role of Antitumor Antibiotics in Current Oncologic Practice

   • H. L. Davis Jr., D. D. Von Hoff, J. E. Henney, M. Rozencweig

   Pages 21-29

4. Historical Overview of the National Cancer Institute Fermentation Program

   • S. A. Schepartz

   Pages 30-32

5. National Cancer Institute’s Fermentation Development Program

   • J. D. Douros

   Pages 33-48

6. In Vivo Antitumor Evaluation of Antibiotics. Selected Results from the Drug Evaluation Program of the National Cancer Institute, U.S.A

   • J. M. Venditti, R. K. Johnson

   Pages 49-57

7. Antitumor Antibiotic Bioactivation, Biotransformation and Derivatization by Microbial Systems

   • J. P. N. Rosazza

   Pages 58-68

8. Detection and Assay of Antitumor Antibiotics

   • L. J. Hanka, S. L. Kuentzel, D. G. Martin, P. F. Wiley, Gary L. Neil

   Pages 69-76

9. Fingerprint Methods used to Identify known Antineoplastic Agents in Culture Filtrates

   • R. H. Bunge, D. E. McCready, L. A. Balta, B. D. Graham, J. C. French, H. W. Dion

   Pages 77-84

10. Microbial Process Translation—Laboratory to Pilot Plant at the Frederick Cancer Research Center

    • A. F. Langlykke

    Pages 85-98

11. Criteria for Selection of New Analogs of Antitumor Antibiotics

    • A. Goldin

    Pages 99-112

12. Preclinical Status of Macromomycin at the National Cancer Institute

    • V. H. Bono Jr, D. Abraham

    Pages 113-119

13. New Microbial Secondary Metabolites Under Preclinical Development for Cancer Treatment

    • H. Umezawa

    Pages 120-134

14. The Current Status of Chemotherapy for Gastric Cancer in Japan with Special Emphasis on Mitomycin C

    • Y. Koyama

    Pages 135-147

15. Mitomycin C: Experience in the United States, with Emphasis on Gastric Cancer

    • P. S. Schein, J. S. MacDonald, D. Hoth, P. V. Woolley

    Pages 148-151

16. A Review of the Bleomycin Experience in the United States

    • M. A. Friedman

    Pages 152-168

17. Combined Use of Bleomycin with Radiation in the Treatment of Cancer

    • M. Abe, Y. Shigematsu, S. Kimura

    Pages 169-178

18. A Sequential Combination of Bleomycin and Mitomycin C in the Treatment of Advanced Squamous Cancers

    • T. Miyamoto

    Pages 179-190

19. Fundamental and Clinical Studies on New Bleomycin Analogs

    • A. Matsuda, O. Yoshioka, T. Yamashita, K. Ebihara, H. Umezawa, T. Miura et al.

    Pages 191-210

20. Experimental Results with the Combination of Bleomycin Plus Mitomycin C

    • N. Yamanaka, M. Fukushima, T. Kato, K. Koizumi, K. Ota

    Pages 211-218

The scientific collaboration between the United States and Japan in the field of cancer goes back many years. In this successful international collaboration cancer chemotherapy has been one of the most productive areas. Pioneers such as YOSHIDA, UMEZAWA, SHEAR, and GOLDIN established firm links of mutual trust and respect in the period after the Second Great War. Japanese drugs, such as mitomycin C and bleomycin have become mainstays of clinical oncology in the U. S. and throughout the world. Many drugs developed in the U. S. have become established in Japanese cancer therapy. Within the cancer chemotherapy field the antitumor antibiotics rank as one of the most important groups. In the U . S. -J apanese collaboration this group of drugs has taken the paramount role. The Japanese, under the leadership of U mezawa, are considered to be among the most innovative and productive in this area which has also had great emphasis in the United States as part of the National Cancer Institute's drug development program and in the pharmaceutical industry. This extended collaboration in general oncology, and chemotherapy in particular, has received increased impetus by and support from the official U . S. -J apan Joint Agreement on cancer research, which was established in 1974 between the National Cancer Institute and the Japanese Society for the Promotion of Science. One of the subsections of this agreement is cancer therapy with emphasis on chemotherapy.

• antibiotics
• cancer
• cancer research
• cancer therapy
• chemotherapy
• oncology
• therapy

• Northern California Cancer Program, Palo Alto, USA

  S. K. Carter

• Department of Antibiotics, National Institutes of Health, Shinagawa-ku, Tokyo, Japan

  Hamao Umezawa

• Division of Cancer Treatment, National Cancer Institute, Silver Spring, USA

  John Douros

• Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Toshima-ku, Tokyo, Japan

  Yoshio Sakurai

Policies and ethics